A breakthrough drug is a significant step forward in the fight against HIV. But without changes in behaviour, infection rates won’t come down.
Articles on Truvada
Displaying all articles
Some countries, like Kenya, Uganda, South Africa, Zambia, and Nigeria, have been more proactive than others, but it is still hard for many to get PrEP.
World AIDS Day on Dec. 1 this year comes at a time when a key step to removing financial barriers to PrEP access in the U.S. faces legal challenges.
Our findings suggest that cabotegravir is much more effective than Truvada in preventing HIV infection in women.
Facebook began blocking ads that linked Truvada and other HIV-related drugs to severe bone and kidney damage based on claims made in lawsuits.
An increase in condomless sex in PrEP users is predictable as preventing HIV is the key motivator for condom use among gay and bisexual men.
The HIV prevention drug Truvada (PrEP) will be listed on the Pharmaceutical Benefits Scheme from this Sunday, moving Australia closer to achieving its goal of ending new HIV transmissions by 2020.
PrEP may be giving some homosexual and heterosexual users a false sense of security.
If the vaginal ring becomes available for commercial use it will become one of the tools in the HIV prevention toolbox for women alongside female condoms and daily pre-exposure prophylaxis.
A new pill available could enable people living with HIV to conceive children through sex without risking the health of their HIV-negative partner.
The latest report from Public Health England revealed that there were more than 100,000 people living with HIV in the UK, with 6,000 new infections last year. Around a quarter of people are unaware they…
Top contributors
-
Assistant Professor of Marketing Weber State University, Weber State University
-
Lecturer in Virology, University of Surrey
-
Principal Research Fellow, Australian Research Centre in Sex, Health and Society, La Trobe University
-
Associate Professor, Monash University
-
Professor of Law, University of Oregon
-
Lecturer in Public Health and Primary Care, Bangor University
-
Associate Professor, Public Health Ethics, School of Population Health, UNSW
-
Director: Clinical Trials, Wits Reproductive Health and HIV Institute, University of the Witwatersrand
-
Associate Professor and Director: Research at the Wits Reproductive Health and HIV Institute I, University of the Witwatersrand
-
Assistant Professor of Social, Behavioral and Population Sciences, Tulane University
-
Director of Research, Massachusetts General Hospital Center for Global Health and Professor of Medicine, Harvard Medical School, Harvard University
-
Professor of medicine and deputy director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town
-
Associate Professor of Health Law, Policy and Management, Boston University